Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

INTRODUCTION: Although second-line immunotherapy obtained better outcomes than chemotherapy for patients with advanced non-small–cell lung cancers (NSCLCs), it is expensive and only a minority of patients seem to benefit, based on early tumor progression post-immunotherapy. Notable host inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales: Dusselier, Matthieu, Deluche, Elise, Delacourt, Nellie, Ballouhey, Julia, Egenod, Thomas, Melloni, Boris, Vergnenègre, Charlotte, Veillon, Rémi, Vergnenègre, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636729/
https://www.ncbi.nlm.nih.gov/pubmed/31314761
http://dx.doi.org/10.1371/journal.pone.0219060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636729/
https://www.ncbi.nlm.nih.gov/pubmed/31314761
http://dx.doi.org/10.1371/journal.pone.0219060

Ejemplares similares